Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Dulaglutide
A GLP-1 receptor agonist studied in type 2 diabetes and weight-management research.
- Half-life (approx.)
- ~5 days (approx., subQ)
- Diluent
- Pre-mixed pen — do not reconstitute
- Common vials
- 0.75, 1.5, 3, 4.5 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist with a modified Fc fusion for weekly dosing, studied extensively in type 2 diabetes trials. Research formulations include pen devices and lyophilized powder for laboratory reference. Once-weekly GLP-1 Fc-fusion with established cardiovascular outcome trial data.
Structure & identity
GLP-1 Fc fusion — 2 GLP-1 analogues linked to IgG4 Fc
Status: FDA-approved (Trulicity).
Mechanism
Dulaglutide is a GLP-1 analogue fused to an IgG4 Fc fragment for extended half-life and weekly administration.
GLP-1 Fc-fusion activates GLP-1R with DPP-4 resistance and albumin-mediated half-life extension. DPP-4-resistant GLP-1R activation with IgG4-Fc-mediated half-life extension.
Studies & clinical programs
AWARD diabetes program(Phase 3)
Type 2 diabetes
- Weekly GLP-1 Fc-fusion dosing with glycemic endpoints.
REWIND cardiovascular outcomes(Phase 3)
Type 2 diabetes
- Long-term MACE evaluation in CV outcomes trial.
Research models in literature
- REWIND cardiovascular trial
- AWARD diabetes program
Literature highlights
- GLP-1 Fc-fusion evaluated in AWARD diabetes and REWIND cardiovascular outcome trials.
- Once-weekly DPP-4-resistant receptor activation with albumin-mediated extension.
- HbA1c and body-weight endpoints benchmarked against other GLP-1 class agents.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 0.75 | 0.5 | 1500.0 | 6.7 | 16.7 | 33.3 |
| 1.5 | 0.5 | 3000.0 | 3.3 | 8.3 | 16.7 |
| 3 | 0.5 | 6000.0 | 1.7 | 4.2 | 8.3 |
| 4.5 | 0.5 | 9000.0 | 1.1 | 2.8 | 5.6 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Often supplied pre-mixed in pens; research formulations vary.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance